<DOC>
	<DOCNO>NCT01102608</DOCNO>
	<brief_summary>To study activity toxicity neoadjuvant regimen include high-dose ifosfamide combination radiotherapy , subsequent surgery , high-risk soft tissue sarcoma .</brief_summary>
	<brief_title>Neoadyuvant High-dose Ifosfamide Concurrent Radiotherapy Soft Tissue Sarcoma</brief_title>
	<detailed_description>This phase II multicenter study design two phase . A total 32 patient include 10 hospital belong Spanish Group Research Sarcomas ( GEIS ) . Selection criterion : patient localize soft tissue sarcoma extremity trunk high-risk feature ( &gt; 5 cm grade 2-3 ) , recurrences prior inadequate surgery . The treatment schedule : initial biopsy , 3 cycle high-dose Ifosfamide , 12 gr/m2 5 day , concurrent Radiotherapy 50 Gy , subsequent wide surgery . To assess predictive factor response combination therapy , DNA RNA extraction perform pretreatment biopsy . DNA use hybridize Affymetrix GeneChip® Human Mapping 500K Array , allow study 500000 SNPs throughout genome . The expression 39000 RNA transcript evaluate employ Affymetrix Genechip Human Genome HG-U133 Plus 2.0 , validate real-time RT-PCR .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<criteria>1 . Patients Advanced Soft Tissue Sarcoma histological proven , potentially resect , locate extremity trunk one follow histological subtypes : leiomyosarcoma , undifferentiated pleomorphic sarcoma , Synovial Sarcoma , Liposarcoma malignant tumour peripheral nerve sheath . 2 . Primary tumour : 1 . Size ³ 5 cm diameter 2 . Histological grade 23 3 . Deep location 3 . No distant metastases 4 . Patients must previously treat Chemotherapy Radiotherapy tumour area . 5 . However patient eligible local relapse previous surgery . 6 . Patients must £18 ³ 65 year old . 7 . Patients must ECOG performance status 0 1 8 . Patients must measurable disease Recist Criteria . 9 . Absolute neutrophil count ³1,500/mm3 , platelet count ³ 100,060 ml/min , creatinine , total bilirubin , ALT AST £ 1.5 time upper limit normal 10 . Signed informed consent prior study specific procedures 1 . Patients cerebral metastasis 2 . Pregnant breast feeding patient . 3 . Active infection concomitant severe illness . 4 . Severe psychiatric illness would make possible obtention inform consent 5 . Concurrent treatment experimental drug within 30 day prior study entry . 6 . History previous treat diagnosed cancer past 5 year , except basocellular cell skin cancer , cervix cancer situ superficial bladder carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>ifosfamide</keyword>
</DOC>